Journal for ImmunoTherapy of Cancer (Nov 2020)
721 AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection
- Els Verdegaal,
- Hergen Spits,
- Remko Schotte,
- Martijn Kedde,
- Gemma Moiset,
- Hans Van Eenennaam,
- Pauline van Helden,
- Sjoerd van der Burg,
- Julien Villaudy,
- Wouter Pos,
- Daniel Go,
- Christien Fatmawati,
- Etsuko Yasuda,
- Madalina Cercel,
- Esmay Frankin,
- Susan van Hal
Affiliations
- Els Verdegaal
- 2Leiden University Medical Center, Leiden, Netherlands
- Hergen Spits
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Remko Schotte
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Martijn Kedde
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Gemma Moiset
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Hans Van Eenennaam
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Pauline van Helden
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Sjoerd van der Burg
- 2Leiden University Medical Center, Leiden, Netherlands
- Julien Villaudy
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Wouter Pos
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Daniel Go
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Christien Fatmawati
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Etsuko Yasuda
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Madalina Cercel
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Esmay Frankin
- 1AIMM Therapeutics, Amsterdam, Netherlands
- Susan van Hal
- 1AIMM Therapeutics, Amsterdam, Netherlands
- DOI
- https://doi.org/10.1136/jitc-2020-SITC2020.0721
- Journal volume & issue
-
Vol. 8,
no. Suppl 3
Abstract
No abstracts available.
